A Study of Onartuzumab (MetMAb) in Combination With Bevacizumab Compared to Bevacizumab Alone or Onartuzumab Monotherapy in Participants With Recurrent Glioblastoma

NCT01632228 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

135

Enrollment

INDUSTRY

Sponsor class

Conditions

Glioblastoma

Interventions

DRUG: Bevacizumab
DRUG: Onartuzumab
DRUG: Placebo

Sponsor

Hoffmann-La Roche